Genopore

Company Overview

Snapshot

Founded in December 2020 by David Baum and Amit Meller, Genopore operates with 1–10 employees. The company has raised a total of $2.7 million across two funding rounds from two investors. In May 2024, Genopore secured a follow-on investment from M Ventures, signaling continued investor confidence in its innovative protein detection technology.

Business overview

Genopore develops a cost-effective solution for whole-protein identification, leveraging advanced chip technology to create a single-molecule, high-sensitivity, and high-accuracy system capable of handling large data volumes. The company's core product aims to enable early detection of cancer and other diseases, with broad applications spanning drug development, clinical diagnostics, agriculture, food production, and academic research. Genopore operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.

Strategic signal

Genopore's May 2024 follow-on investment from M Ventures highlights ongoing strategic validation for its semiconductor-based protein detection platform. This continued backing from a corporate venture capital firm with a focus on life sciences underscores the potential impact of Genopore's technology in addressing critical needs across medical diagnostics and research, signaling a positive trajectory for product development and market penetration.

Company Intelligence Q&A

What is Genopore's primary focus?

Genopore focuses on developing a cost-effective solution for whole-protein identification using advanced chip technology for high-sensitivity and high-accuracy detection.

When was Genopore founded and by whom?

Genopore was founded in December 2020 by David Baum and Amit Meller.

What are the potential applications of Genopore's technology?

Genopore's technology has potential applications in early detection of cancer and other diseases, drug development, clinical settings, agriculture, food production, and academic research.